Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Follow-Up and Dose Escalation of PF-06838435 in Hemophilia B
NCT03307980Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jun 2017
- Primary completion
- Jul 2026
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 4
01
Overview
A Phase 2 trial of fidanacogene elaparvovec in hemophilia B (HB), sponsored by Pfizer. Started Jun 2017; status: terminated.
02
Drugs
fidanacogene elaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT03307980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03307980.